Application Ser. No.: 10/511,886
Filing Date: October 19, 2004
Examiner: Perlinger, Sarah E

## Amendment Pursuant to 37 C.F.R. § 1.121

***IN THE CLAIMS:***

The claims set forth below with amendments as indicated will replace all prior versions and listing of claims in the application.

1. **(currently amended)** ~~Compound~~ A compound in the form of ~~a pure optical isomer~~ an enantiomer (1*R*,2*R*) or (1*S*,2*S*) or in the form of a threo diastereoisomer, corresponding to general formula (I)



(I)

in which A represents

~~either~~ a group of general formula N-$R_1$, a group of general formula $N^+(O^-)R_1$ or a group of general formula $N^+(R')R_1$, and in which $R_1$ represents either a hydrogen atom, or a linear or branched ($C_1$-$C_7$)alkyl group optionally substituted with one or more fluorine atoms, or a ($C_4$-$C_7$)cycloalkyl group, or a ($C_3$-$C_7$)cycloalkyl($C_1$-$C_3$)alkyl group, or a phenyl($C_1$-$C_3$)alkyl group optionally substituted with one or two hydroxyl or methoxy groups, or a ($C_2$-$C_4$)alkenyl group, or a ($C_2$-$C_4$)alkynyl group,

~~or a group of general formula $N^+(O^-)R_1$ in which $R_1$ is as defined above,~~

~~or alternatively a group of general formula $N^+(R')R_1$ in which~~ R' represents a linear or branched ($C_1$-$C_7$)alkyl group ~~and $R_1$ is as defined above,~~

X represents a hydrogen atom or one or more substituents chosen from halogen atoms and trifluoromethyl, linear or branched ($C_1$-$C_4$)alkyl and ($C_1$-$C_4$)alkoxy groups,

$R_2$ represents either a hydrogen atom, or one or more substituents chosen from halogen atoms and trifluoromethyl, ($C_1$-$C_4$)alkyl or ($C_1$-$C_4$)alkoxy groups, or amino groups of general formula $NR_3R_4$ in which $R_3$ and $R_4$ each represent, independently of each other, a

hydrogen atom or a ($C_1$-$C_4$)alkyl group, or form with the nitrogen atom carrying them a pyrrolidine, piperidine or morpholine ring, or a phenyl group optionally substituted with an atom or a group as defined for the symbol X above;
in the form of a free base or of an addition salt with an acid.

2. **(previously presented)** A compound according to Claim 1 wherein it has the configuration (1*S*,2*S*) and in that $R_2$ represents one or more halogen atoms or trifluoromethyl groups.

3. **(previously presented)** A compound according to Claim 1 wherein it has the configuration (1*R*,2*R*) and in that $R_2$ represents a halogen atom and an amino group of general formula $NR_3R_4$ as defined in Claim 1.

4. **(cancelled)**

5. **(previously presented)** A pharmaceutical composition comprising a compound according to Claim 1 combined with an excipient.

6. **(original)** 2-Chloro-*N*-[(*S*)-phenyl-[(2*S*)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide according to claim 1.

7. **(original)** 2-Chloro-*N*-[(*S*)-phenyl-[(2*S*)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide hydrochloride 1:1 according to claim 6.

8. **(original)** A pharmaceutical composition comprising a compound according to Claim 2 combined with an excipient.

9. **(original)** A pharmaceutical composition comprising a compound according to Claim 3 combined with an excipient.

Application Ser. No.: 10/511,886
Filing Date: October 19, 2004
Examiner: Perlinger, Sarah E

10. **(original)** A pharmaceutical composition comprising a compound according to Claim 6 combined with an excipient.

11. **(original)** A pharmaceutical composition comprising a compound according to Claim 7 combined with an excipient.

12. - 16. **(cancelled)**

17. **(new)** A compound according to claim 1 wherein A represents a group of general formula N-$R_1$ in which $R_1$ represents either a hydrogen atom, or a linear or branched ($C_1$-$C_7$)alkyl group optionally substituted with one or more fluorine atoms and said compound in the form of a free base or of an addition salt with an acid.

18. **(new)** A compound according to claim 1 which is selected from the group consisting of:

- threo-2-chloro-*N*-[(1-ethylpiperidin-2-yl)phenylmethyl]-3-trifluoromethylbenzamide hydrochloride;
- threo-2-chloro-*N*-[(1-ethylpiperidin-2-yl)phenylmethyl]-3-trifluoromethylbenzamide;
- 2-chloro-*N*-[(1*S*)-[(2*S*)-1-methylpiperidin-2-yl]phenylmethyl]-3-trifluoromethyl-benzamide hydrochloride;
- 2-chloro-*N*-[(1*S*)-[(2*S*)-1-methylpiperidin-2-yl]phenylmethyl]-3-trifluoromethyl-benzamide;
- threo-4-amino-3-chloro-*N*-[(1-methylpiperidin-2-yl)phenylmethyl]-5-trifluoromethyl-benzamide hydrochloride;
- threo-4-amino-3-chloro-*N*-[(1-methylpiperidin-2-yl)phenylmethyl]-5-trifluoromethyl-benzamide;

- 4-amino-3-chloro-*N*-[(1*R*)-[(2*R*)-1-methylpiperidin-2-yl]phenylmethyl]-5-trifluoromethylbenzamide hydrochloride;
- 4-amino-3-chloro-*N*-[(1*R*)-[(2*R*)-1-methylpiperidin-2-yl]phenylmethyl]-5-trifluoromethylbenzamide;
- threo-2-chloro-*N*-[phenyl(piperidin-2-yl)methyl]-3-trifluoromethylbenzamide hydrochloride;
- threo-2-chloro-*N*-[phenyl(piperidin-2-yl)methyl]-3-trifluoromethylbenzamide;
- 2-chloro-*N*-[(*S*)-phenyl-[(2*S*)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide hydrochloride;
- 2-chloro-*N*-[(*S*)-phenyl-[(2*S*)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide;
- 2-chloro-*N*-[[1-methyl-1-oxido-piperidin-2-yl](phenyl)methyl]-3-trifluoromethylbenzamide; and
- 2(*S*)-2[(1*S*)-[[2-chloro-3-(trifluoromethyl)benzoyl]amino](phenyl)methyl]-1,1-dimethylpiperidinium iodide or

a pharmaceutically acceptable salt thereof.

19. (new) 2-chloro-*N*-[(1*S*)-[(2*S*)-1-methylpiperidin-2-yl]phenylmethyl]-3-trifluoromethylbenzamide according to claim 1.

20. (new) 2-chloro-*N*-[(1*S*)-[(2*S*)-1-methylpiperidin-2-yl]phenylmethyl]-3-trifluoromethylbenzamide hydrochloride 1:1 according to claim 1.

21. (new) 4-amino-3-chloro-*N*-[(1*R*)-[(2*R*)-1-methylpiperidin-2-yl]phenylmethyl]-5-trifluoromethylbenzamide hydrochloride 1:1 according to claim 1.

22. (new) A pharmaceutical composition comprising a compound according to Claim 18 combined with an excipient.

23. (new) A pharmaceutical composition comprising a compound according to Claim 19 combined with an excipient.

24. (new) A pharmaceutical composition comprising a compound according to Claim 20 combined with an excipient.

25. (new) A pharmaceutical composition comprising a compound according to Claim 21 combined with an excipient.

26. (new) A method for the treatment of a disorder associated with glyt1 glycine transporter comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 1.

27. (new) A method for the treatment of a disorder associated with glyt1 glycine transporter comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 2.

28. (new) A method for the treatment of a disorder associated with glyt1 glycine transporter comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 6.

29. (new) A method for the treatment of a disorder associated with glyt1 glycine transporter comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 7.

30. (new) A method for the treatment of a disorder associated with glyt1 glycine transporter comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 17.

31. (new) A method for the treatment of a disorder associated with glyt1 glycine transporter comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 18.

32. (new) A method for the treatment of a disorder associated with glyt1 glycine transporter comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 19.

33. (new) A method for the treatment of a disorder associated with glyt1 glycine transporter comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 20.

34. (new) A method for the treatment of a disorder associated with glyt2 glycine transporter comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 1.

35. (new) A method for the treatment of a disorder associated with glyt2 glycine transporter comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 3.

36. (new) A method for the treatment of a disorder associated with glyt2 glycine transporter comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 17.

Application Ser. No.: 10/511,886
Filing Date: October 19, 2004
Examiner: Perlinger, Sarah B

37. (new) A method for the treatment of a disorder associated with glyt2 glycine transporter comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 18.

38. (new) A method for the treatment of a disorder associated with glyt2 glycine transporter comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 21.